Excerpts

It was associated with lower adherence and more frequent adverse events than placebo, and did not improve cognition, mental well-being, or blood pressure; only a nonsignificant trend toward reduced white matter hyperintensity progression was observed ( 92 ).

The reported immunogenicity data suggest a slight trend toward higher ADA incidence in humanized compared to fully human anti-PD-1 antibodies.

Although KLRG1 expression showed a nominally significant regional difference, this association did not remain statistically significant after FDR correction (q = 0.17).

Sm -infected mice also showed a trend toward lower levels of spike-specific Th2 cytokines (IL-4 and IL-5) compared to non-infected mice ( Figure 2H ), and lower SEA-specific Th2 cytokines (IL-5 and IL-10) compared to the 8-week Sm infection group ( Supplementary Figures 1E , 2C ), possibly reflecting overall immunosuppression during the chronic infection phase of Schistosoma ( 28 ), though these differences were not statistically significant.

Volcano plot analysis across all patients identified TOX2 (log 2 FC = 0.605, −log 10 (padj) = 2.57) and PDCD1 (log 2 FC = 0.810, −log 10 (padj) = 2.59) as reaching both the fold-change (|log 2 FC| > 0.3) and significance (padj < 0.05) thresholds; CD274, LAG3, and IDO1 also approached significance ( Figure 2b ).

While MT patients showed a trend toward decreased CD4 + T cell and increased CD8 + T cells, the change was not statistically significant ( P = 0.0681 ).

As shown in the heatmap ( Figure 1A ), genes associated with cDC1, cDC2, pDC, and Th2 cells showed an overall trend toward upregulation in AD patients compared to HCs, whereas Treg markers showed variable changes.

The dataset over the course of the study showed no significant trend at 25 °C (with the exception of particle size [D90] for SEnGMMA/Alhydrogel for which an increasing trend was identified) and 37 °C for S.

To ensure the observed performance exceeded random chance, we performed 1,000-fold permutation testing, yielding a highly significant empirical p-value of 0.0030.

3.2.3 Subgroup analysis for overall survival by PD-L1 expression 3.2.3.1 PD-L1 <1% For SQ-NSCLC (data from 7 trials involving 1, 047 patients and 7 ICI combination regimens), nivolumab plus ipilimumab was associated with prolonged OS compared with atezolizumab plus chemotherapy (HR = 0.56, 95% CrI: 0.32–0.98) and showed a trend toward improved OS compared with pembrolizumab plus chemotherapy (HR = 0.59, 95% CrI: 0.33–1.05); it was ranked as the most effective regimen (SUCRA = 0.83).

The correlation results clearly showed that MAPKAPK3 was the most prominent gene, exhibiting highly significant correlations with both independent risk models.

In the KEYNOTE-789 study, in the PD-L1-positive subgroup, the Pembrolizumab plus chemotherapy group showed a trend toward improved OS ( 23 ).

However, it is noteworthy that the survival advantage of CAR-T therapy remained highly significant (HR = 0.31 for OS) even after rigorous adjustment for these baseline imbalances and TP53 status in our multivariable model.

Immune infiltration analysis showed that neutrophils, macrophages, and some T cell subsets were significantly enriched in samples with high ASS, while dendritic cells and B cells showed a decreasing trend ( Figure 7D ), suggesting a strong link between ASS and immune microenvironment activation.

For short-term poor prognosis, multivariate logistic regression showed that elevated TyG index was an independent risk factor, with a borderline significant P value of 0.068.

TyG quartile-stratified GBS patient characteristics are presented in Table 4 , with a notable trend of increasing age in patients with higher TyG index.

Although the changes in glud1 and glul expression were not statistically significant but showed a decreasing trend, suggesting partial amelioration of the nitrogen metabolism disorder by the ZO-1 agonist. 3.4 The ZO-1 agonist is associated with preservation of TJ protein complex organization GSEA ( Figures 5A–C ) revealed that the TJ pathway (KO04530) was significantly upregulated in the Control vs.

Mechanistically, Semen Cuscutae remodeled the osteoimmune microenvironment by suppressing pro-inflammatory cytokines (IL-6) and bone resorption markers (TRACP, CTX, RANKL), while ALP showed an increasing trend and osteogenic or reparative factors, including OPG, IGF, and TGF-β, were significantly upregulated.

Following hUC-MSC infusion, T cells and NK cells showed a trend of increase at Day 7 and Day 14, while B cell counts remained relatively stable ( Figure 5 ).

Of note, this atypical memory B-cell subset demonstrated a decreasing trend, representing 4.5% of the total B-cell compartment at the last follow-up.

Mepolizumab significantly improved nasal obstruction VAS score from baseline to weeks 49–52 compared with placebo, with a mean treatment difference of −1.43, and showed a numerical trend toward improvement in total endoscopic nasal polyp score at week 52, with a mean treatment difference of −0.43 ( 107 ).

Intriguingly, a group of unclassified bacteria, designated as “unclassified_Bacteria,” displayed the broadest and strongest positive correlations across nearly all inflammatory and disease activity measures, reaching statistical significance with CRP (ρ = 0.44, P = 0.015) and showing a notable trend with RF positivity (see below).

The strong correlation between Escherichia/Shigella abundance and DAS28-ESR, which remained as a significant trend, suggests that this organism may contribute meaningfully to the systemic inflammatory burden in RA-ILD patients.

MR analysis confirmed that downregulation of PRR4 expression is a risk factor for CRSwNP (OR = 0.99951, P = 0.04280), with the caveat that the very small effect size and borderline significance indicate limited evidence strength at present.

MR analysis preliminarily suggested that IL4R and IMPA2 may be potential risk factors for CRSwNP, while PRR4 may serve as a potential protective factor, though the effect sizes were modest (OR values close to 1) and P values were borderline significant (0.043–0.045), indicating limited evidence strength.